Research Article
Antifibrotic Therapy in the Treatment of Patients with Pulmonary Manifestations in Complicated COVID-19
Issue:
Volume 15, Issue 2, June 2026
Pages:
16-20
Received:
5 March 2026
Accepted:
17 April 2026
Published:
16 May 2026
Abstract: The study assessed the efficacy and safety of Longidaza® (bovhyaluronidase azoximer, 3000 IU) in patients with lung damage after complicated COVID‑19. Two groups of 30 patients each were compared: the first received Longidaza® via intramuscular injections (3000 IU every five days, 15 injections total); the second was under dynamic observation without active therapy. The trial ran from August to December 2023. Participants were over 18 years old, had lung manifestations after severe COVID‑19, started outpatient treatment within two months after hospital discharge, and provided informed consent. Exclusion criteria included pregnancy, lactation, severe comorbidities, etc. Key parameters after 10 weeks (day 71) were changes in: resting capillary blood oxygen saturation (SpO2,%); laboratory markers (lymphocytes, C‑reactive protein [CRP], D-dimer, fibrinogen). Statistical analysis used Stata 14.0 (significance level: p < 0,05; Mann‑Whitney test). Mean age was 59.8 ± 15.2 years (Longidaza group) and 56.06 ± 13.7 years (observation group). Common comorbidities: hypertension and coronary heart disease. Results: CRP levels decreased more than twofold in both groups (to 3.66 ± 3.84 mg/L and 1.24 ± 0.7 mg/L, respectively). Blood oxygen saturation stayed ≥ 96% in most patients. In the Longidaza group, some parameters were statistically significantly lower — possibly indicating antifibrotic activity. No adverse effects were reported. Conclusion: Longidaza® is safe and potentially effective for preventing and treating early pneumofibrosis and managing established lung fibrosis.
Abstract: The study assessed the efficacy and safety of Longidaza® (bovhyaluronidase azoximer, 3000 IU) in patients with lung damage after complicated COVID‑19. Two groups of 30 patients each were compared: the first received Longidaza® via intramuscular injections (3000 IU every five days, 15 injections total); the second was under dynamic observation witho...
Show More
Case Report
Potential for Corneal Recovery During Nonstandard Rehabilitation After LASIK
Galina Romanovna Semak,
Volha Ivanovna Remezava*
,
Yuliya Vladimirovna Markava,
Gleb Valerievich Krishtopenko
Issue:
Volume 15, Issue 2, June 2026
Pages:
21-26
Received:
21 July 2026
Accepted:
3 August 2026
Published:
20 August 2026
Abstract: Laser in situ keratomileusis (LASIK) provides predictable refractive outcomes, but clinically silent epithelial basement membrane dystrophy (EBMD) may become apparent during flap creation and lead to epithelial sloughing, delayed epithelial recovery, and postoperative ocular surface instability. This case report describes the management of a 30-year-old man with bilateral moderate myopia and astigmatism who underwent microkeratome-assisted LASIK after a routine preoperative examination showed no corneal epithelial abnormalities. The baseline Ocular Surface Disease Index score was 6, tear breakup time was 7 seconds in the right eye and 8 seconds in the left eye, and anterior-segment optical coherence tomography showed tear meniscus heights of 304 and 299 micrometers, respectively. During flap repositioning, the epithelium demonstrated abnormal mobility, folding, and focal sloughing. On postoperative day 1, the right eye had uncorrected visual acuity of 0.6-0.7, diffuse epithelial edema, and a central epithelial defect; the left eye had uncorrected visual acuity of approximately 1.0. Subconjunctival dexamethasone was administered because of the risk of diffuse lamellar keratitis. At 1 week, persistent grade 1-2 epitheliopathy and early epithelial ingrowth were observed. Treatment was supplemented with three weekly bilateral subconjunctival injections of 1% low-molecular-weight sodium hyaluronate, followed by monthly injections, together with topical corticosteroids and hyaluronic-acid lubricants. During follow-up, epithelial staining decreased, epithelial morphology on optical coherence tomography became more uniform, visual acuity remained stable, and subjective discomfort improved. At 2 months, the Ocular Surface Disease Index score decreased to 3, Schirmer test values increased to 26 and 28 mm, tear breakup time increased to 9 and 10 seconds, and tear meniscus height increased to 476 and 504 micrometers. This case suggests that multimodal regenerative therapy including subconjunctival low-molecular-weight sodium hyaluronate may support corneal epithelial recovery after intraoperative manifestation of EBMD during LASIK; controlled studies are required to determine efficacy.
Abstract: Laser in situ keratomileusis (LASIK) provides predictable refractive outcomes, but clinically silent epithelial basement membrane dystrophy (EBMD) may become apparent during flap creation and lead to epithelial sloughing, delayed epithelial recovery, and postoperative ocular surface instability. This case report describes the management of a 30-yea...
Show More
